Thrombosis research
-
Thrombosis research · Jan 2007
A novel intermittent mechanical compression device for stasis prevention in the lower limbs during limited mobility situations.
Intermittent pneumatic mechanical compression is commonly applied to obviate venous stasis in patients with increased risk of thromboembolism. Aviafit is a small battery-operated intermittent compression device using a patented mechanical, non-pneumatic technology. Our objective was to examine its ability to prevent venous stasis. ⋯ The lightweight, battery-operated and user-friendly Aviafit can provide the same hemodynamic benefits as larger conventional intermittent pneumatic compression devices. Its potential advantages for prophylaxis of thromboembolism and increased compliance in rehabilitation and homecare, and for use during long periods of immobility such as during flights, are evident.
-
Thrombosis research · Jan 2007
Cinnamaldehyde reduction of platelet aggregation and thrombosis in rodents.
Cinnamaldehyde (CA) has been reported to inhibit in vitro aggregation in human and rabbit platelets; however, little is known about the antithrombotic activities of CA in vivo. ⋯ The results demonstrate that CA may be a promising antithrombotic agent, and its antithrombotic activity may be due to anti-platelet aggregation activity in vitro and in vivo.
-
Thrombosis research · Jan 2007
ReviewWhat is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Pulmonary embolism after acute ischemic stroke (AIS) is associated with a high in-hospital mortality. The benefit from pharmacological prophylaxis for venous thromboembolism (VTE) is uncertain probably due to doubts about the optimal agent and dose. We evaluated the benefit/risk ratio of different anticoagulant regimens in the prevention of VTE in patients with AIS. ⋯ Indirect comparison of low and high doses of UFH and LMWH suggests that low-dose LMWH have the best benefit/risk ratio in patients with acute ischemic stroke by decreasing the risk of both DVT and pulmonary embolism, without a clear increase in ICH or ECH.
-
Thrombosis research · Jan 2007
Randomized Controlled Trial Comparative Study Clinical TrialFactor XIII in severe sepsis and septic shock.
In sepsis, activation of coagulation and inhibition of fibrinolysis lead to microvascular thrombosis. Thus, clot stability might be a critical issue in the development of multiple organ dysfunction syndrome. Activated FXIII (FXIIIa) forms stable fibrin clots by covalently cross-linking fibrin monomers. Therefore, we investigated the impact of FXIII antigen and activity levels on disease severity and fatality in sepsis patients. ⋯ We show decreased FXIIICA and FXIIIA levels, but higher SA(FXIII) in sepsis as compared to controls. Increased SA(FXIII) correlates with disease severity and fatality in sepsis patients.
-
Thrombosis research · Jan 2007
Multicenter Study Clinical TrialProthrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation.
Rapid reversal of anticoagulant effect from the use of vitamin K antagonists (VKA) is essential when acute bleeding or emergency surgery occurs. Prothrombin complex concentrates (PCCs) produce a more rapid effect with a better clinical outcome, and do not cause volume overload as compared with fresh-frozen plasma (FFP). Octaplex is a modern, double virus safeguarded PCC with balanced content of vitamin K-dependent coagulation factors, which ensures fast onset of action and efficacious treatment, i.e. rapid correction of international normalized ratio (INR). ⋯ Octaplex is efficacious and safe in immediate correction of dosage-dependent INR in patients with VKA-related deficiency of prothrombin complex coagulation factors.